Revvity Sch 23390, -, 1mci (37mbq)

Revvity 1mCi quantities of SCH 23390, [N-Methyl-³H]-, are available for your research. SCH-23390 acts as an antagonist at the dopamine D₁ receptor. These receptors belong a family of GPCRs and are potential drug targets for Parkinsons disease, schizophrenia, and depression. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity References for NET930: - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Finnema, S.J., Bang-Andersen, B., Jørgensen, M., Christoffersen, C.T., Gulyás, B., WikströM, H.V., Farde, L. and Halldin, C. (2013), The dopamine D1 receptor agonist (S)-[11C]N-methyl-NNC 01-0259 is not sensitive to changes in dopamine concentration—a positron emission tomography examination in the monkey brain. Synapse, 67: 586–595.Wong, J., Clifford, J., Massalas, J., Finkelstein, D., Horne, M., Waddington, J., Drago, J. (2003) Neurochemical changes in dopamine D1, D3 and D1/D3 receptor knockout mice, European Journal of Pharmacology, 472 (1–2): 39-47.